MX2017014301A - Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. - Google Patents
Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.Info
- Publication number
- MX2017014301A MX2017014301A MX2017014301A MX2017014301A MX2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary hypertension
- prevention
- treatment
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona composiciones y métodos para el tratamiento o prevención de hipertensión pulmonar que comprenden administrar una ascomicina, o una sal, solvato, análogo, o profármaco farmacéuticamente aceptable de la misma al paciente con hipertensión pulmonar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562159162P | 2015-05-08 | 2015-05-08 | |
PCT/US2016/030737 WO2016182813A1 (en) | 2015-05-08 | 2016-05-04 | Compositions and methods for the treatment or prevention of pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014301A true MX2017014301A (es) | 2018-03-23 |
Family
ID=57249333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014301A MX2017014301A (es) | 2015-05-08 | 2016-05-04 | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. |
Country Status (10)
Country | Link |
---|---|
US (3) | US20180125828A1 (es) |
EP (1) | EP3294294A4 (es) |
KR (1) | KR20180002822A (es) |
CN (1) | CN107708695A (es) |
AU (1) | AU2016262391A1 (es) |
BR (1) | BR112017023817A2 (es) |
CA (1) | CA2985080A1 (es) |
MX (1) | MX2017014301A (es) |
RU (1) | RU2017142589A (es) |
WO (1) | WO2016182813A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11417416B2 (en) * | 2018-06-14 | 2022-08-16 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE268185T1 (de) * | 2000-07-14 | 2004-06-15 | Healthecon Ag | Grüntee-extrakt zur behandlung von cyclosporin oder ascomycin induzierten nieren- funktionsstörungen |
GB0108498D0 (en) * | 2001-04-04 | 2001-05-23 | Novartis Ag | Organic Compounds |
FI3821891T3 (fi) * | 2011-05-02 | 2023-08-24 | Univ Leland Stanford Junior | FK506:n käyttö pulmonaarisen valtimohypertension hoidossa |
US20130225595A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
-
2016
- 2016-05-04 RU RU2017142589A patent/RU2017142589A/ru unknown
- 2016-05-04 AU AU2016262391A patent/AU2016262391A1/en not_active Abandoned
- 2016-05-04 WO PCT/US2016/030737 patent/WO2016182813A1/en active Application Filing
- 2016-05-04 BR BR112017023817A patent/BR112017023817A2/pt not_active Application Discontinuation
- 2016-05-04 CA CA2985080A patent/CA2985080A1/en not_active Abandoned
- 2016-05-04 CN CN201680040020.9A patent/CN107708695A/zh active Pending
- 2016-05-04 US US15/572,487 patent/US20180125828A1/en not_active Abandoned
- 2016-05-04 MX MX2017014301A patent/MX2017014301A/es unknown
- 2016-05-04 EP EP16793203.7A patent/EP3294294A4/en not_active Withdrawn
- 2016-05-04 KR KR1020177035083A patent/KR20180002822A/ko not_active Application Discontinuation
-
2019
- 2019-03-21 US US16/360,114 patent/US20200054613A1/en not_active Abandoned
-
2021
- 2021-07-12 US US17/373,006 patent/US20210338642A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3294294A4 (en) | 2019-01-02 |
US20200054613A1 (en) | 2020-02-20 |
RU2017142589A3 (es) | 2019-09-26 |
RU2017142589A (ru) | 2019-06-10 |
AU2016262391A1 (en) | 2017-11-23 |
BR112017023817A2 (pt) | 2018-07-31 |
US20180125828A1 (en) | 2018-05-10 |
CN107708695A (zh) | 2018-02-16 |
US20210338642A1 (en) | 2021-11-04 |
EP3294294A1 (en) | 2018-03-21 |
CA2985080A1 (en) | 2016-11-17 |
KR20180002822A (ko) | 2018-01-08 |
WO2016182813A1 (en) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
PH12016502256A1 (en) | Medical use | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
NZ735044A (en) | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | |
MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
MX2017004440A (es) | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. | |
MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
MX2022013450A (es) | Formulaciones farmaceuticas. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. | |
TR201714882A2 (tr) | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
IN2014MU00859A (es) | ||
MX2019008847A (es) | Profarmacos de cisteamina. | |
MX2018012587A (es) | (+)-azasetron para uso en el tratamiento de trastornos del oido. | |
MX2017002747A (es) | Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak. | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
IN2014DE00822A (es) |